Research at CMH

A study of Remternetug vs. Placebo in Early Alzheimer’s Disease Participants at Risk For Cognitive and Functional Decline.

Early Alzheimer’s Disease study: Phase 2. randomized, Placebo-controlled, parallel group, 72-week study to evaluate the efficacy and safety of VHB937 in participants with early Alzheimer’s Disease followed by an open-label extension.

Official Title: A Study of Remternetug in Participants With Alzheimer's Disease

Study Purpose: To collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease.

Official Title: A Study of Donanemab in Participants With Early Alzheimer's Disease

Study Purpose: To see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

Official Title: A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease

Study Purpose: To evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease.

Evaluation of P-tau 217 assay by measuring changes in the intended patient management between pre- and post P-tau 217 results: a randomized clinical utility study.

Official Title: A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

Study Purpose: To evaluate the effect of erenumab on medication-specific treatment s

Official Title: A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

Study Purpose: To evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.

Official Title: A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Study Purpose: The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).

Official Title: A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease

Study Purpose: This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either the double-blind or open-label extension (OLE) part.

Official Title: Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease

Study Purpose: This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 116. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

Official Title: A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Study Purpose: The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult patients with migraine and major depressive disorder (MDD). The secondary objectives are to evaluate the efficacy of monthly 225 mg sc of fremanezumab in adult patients with migraine and MDD on the reduction of MDD symptoms, responder rates in monthly migraine days, improving quality of life, improving disability, and the safety and tolerability of monthly 225 mg sc and quarterly 675 mg sc fremanezumab in adult patients with migraine and MDD.

Official Title: A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

Study Purpose: Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in subjects with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication overuse headache (MOH).

Official Title: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects with Episodic Migraines

Study Purpose: To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.